Toujeo

Insulin glargine

DM in adults, adolescents & childn ≥6 yr.

SC Individualized dosage. Type 1 DM Once daily w/ short-/rapid-acting insulin & requires individual dose adjustments. Type 2 DM Initially 0.2 u/kg followed by individual dose adjustments, may be given w/ other antihyperglycaemic products.

Hypersensitivity.

Not to be administered IV & not to be used in insulin infusion pumps. Perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy & cutaneous amyloidosis. Not for diabetic ketoacidosis. Patients w/ significant coronary arteries stenoses or blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia), proliferative retinopathy; patients in whom glycaemic control is markedly improved, whom hypoglycaemia develops gradually & whom an autonomic neuropathy is present, after transfer from animal insulin to human insulin, long history of diabetes, suffering from a psychiatric illness, receiving concurrent treatment w/ certain other medicinal products; change in the inj area, improved insulin sensitivity (eg, removal of stress factors), unaccustomed, increased or prolonged physical activity, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, hypothyroidism & anterior pituitary or adrenocortical insufficiency). Switching between insulin glargine 100 u/mL & Toujeo (recommended to frequently monitor plasma glucose level during 1st wk of switch); switching to another type or brand of insulin; change in strength, brand, type, origin &/or method of manufacture. Intercurrent illness requires intensified metabolic monitoring. Formation of insulin Abs. Risk of cardiac failure w/ pioglitazone. Renal or hepatic impairment. May affect ability to drive & use machines. Pregnancy & lactation. Childn <6 yr. Elderly ≥65 yr.

Hypoglycaemia. Lipohypertrophy; inj site reactions.

Enhanced blood glucose-lowering effect w/ anti-hyperglycaemics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamides. Reduced blood glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. Potentiated or weakened blood glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypoglycaemia followed by hyperglycaemia w/ pentamidine. Reduced or absent signs of adrenergic counterregulation w/ β-blockers, clonidine, guanethidine & reserpine.

Antidiabetic Agents

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

POM